登录注册

Decondensing cancer immunotherapy

Science

T cell activation predicates important immune responses. Programmed cell death protein 1 (PD-1) controls the overstimulation of T cells, and inhibiting PD-1 has been a successful strategy for immune-checkpoint cancer immunotherapy. Still, the precise mechanism by which PD-1 turns off T cells is not entirely clear. A better understanding could enable the design of more effective cancer drugs. Sharma et al. offer a new model for PD-1–mediated suppression of T cell function. Whereas other models focus on PD-1–mediated inhibitory effects on key signaling molecules in T cells, the authors propose that PD-1 dissolves biomolecular condensates (phase-separated droplet-like bodies) that are thought to amplify T cell signaling. The study offers a conceptually new framework for the negative regulation of T cell function that is potentially of therapeutic relevance.

Related products

Catalog No.	Product Name	Description	Target
HS870026	Anti-Human PD-1 Reference Antibody (Pembrolizumab	Pembrolizumab (HS870026) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.	CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

鄂ICP备2023002448号-2

重组蛋白

抗体

试剂盒

实验相关试剂

Decondensing cancer immunotherapy